Psoriasis Genetic Testing Now Available in Europe

A new genetic test for psoriatic arthritis is now available in Europe as a CE in vitro diagnostic medical device. DermaGenoma, Inc., a molecular dermatology research and development innovator announced the unveiling of the genetic testing system in late July, 2010 and the device is now available under the European In Vitro Diagnostic Directive.

The PsoriasisDX Genetic Test for Psoriatic Arthritis(PsA) is available as a CE marked product, a requirement established by European Directives that ensures conformity and compliance. The testing device is designed to identify those who are at a high risk for developing psoriatic arthritis before they even experience the arthritic symptoms, making it easier for doctors to assess joint damage and proceed with medical intervention if necessary.

According to Andy Goren, CEO of DermaGenoma, Inc.,”We  are excited to extend this revolutionary genetics testing breakthrough to dermatologists in Europe…it helps doctors determine the proper treatments for patients.”

Psoriasis is a chronic skin disease that causes skin to develop thick, silvery scales and raised red skin.  It is considered to be a non-curable condition that progressively worsens over time, but some people may be clear of the condition during periods of remission throughout the course of their lives. The skin condition can occur in all races, both sexes, and in people of all ages, and may become aggravated by extreme temperatures or increased exposure to sunlight.

The cause of psoriasis is unknown, but dermatologists and skin care professionals are able to treat various stages of the condition using certain topical creams, lotions and sprays, or by injecting steroids directly into the skin. Patients who have moderate to severe psoriasis may be good candidates for prescription medication such as methotrexate or even light therapy which can help to improve the health and condition of the skin.

Genetic testing will help many medical professionals detect and diagnose the disease early, and may help the patient prepare for an effective treatment plan.

Further Reading

  • Up until now, dermatologists have been trying a variety of different skin removal techniques to get rid of precancerous skin lesions.

  • Topical agents, diet and certain medicines presented at the American Academy of Dermatology’s Summer Academy Meeting 2010 in Chicago is showing promise for preventing UV-induced skin cancer. Most skin cancers are caused by overexposure to ultraviolet radiation, and dermatologists are now encouraging the public to be conscientious about the amount of sun they are exposed to, and taking extra steps to use broad-spectrum sunscreen on a regular basis.

  • Individuals with a rare skin disease called recessive dystrophic epidermolysis bullosa (RDEB) can improve their condition with the transfer of bone marrow stem cells. A team of medical researchers has found that bone marrow stem cells can effectively treat the disease and help to repair the skin and speed up the healing process. This skin disease cannot be treated with conventional dermatology procedures.